Leo Wealth LLC Boosts Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Leo Wealth LLC grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 85.7% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,179 shares of the biopharmaceutical company's stock after acquiring an additional 544 shares during the period. Leo Wealth LLC's holdings in Regeneron Pharmaceuticals were worth $748,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the stock. Pinney & Scofield Inc. bought a new stake in Regeneron Pharmaceuticals during the 4th quarter valued at $25,000. E Fund Management Hong Kong Co. Ltd. grew its position in shares of Regeneron Pharmaceuticals by 344.4% in the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 31 shares in the last quarter. Avalon Trust Co purchased a new position in shares of Regeneron Pharmaceuticals in the fourth quarter valued at $36,000. Crowley Wealth Management Inc. bought a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at $36,000. Finally, Tompkins Financial Corp purchased a new stake in Regeneron Pharmaceuticals during the 1st quarter worth about $32,000. Hedge funds and other institutional investors own 83.31% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on REGN shares. Argus cut Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Monday, June 30th. The Goldman Sachs Group reduced their price objective on shares of Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating for the company in a research note on Wednesday, April 30th. JPMorgan Chase & Co. cut their price target on shares of Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating for the company in a report on Monday, June 9th. Wall Street Zen downgraded Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 1st. Finally, Wells Fargo & Company lowered Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and decreased their target price for the stock from $700.00 to $580.00 in a research note on Friday, May 30th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have issued a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $823.54.

Regeneron Pharmaceuticals Trading Down 4.0%

REGN stock traded down $22.63 during trading on Tuesday, hitting $547.96. 998,434 shares of the company traded hands, compared to its average volume of 918,917. The company has a 50-day moving average of $544.56 and a 200-day moving average of $618.18. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.03 and a current ratio of 4.93. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $1,211.20. The firm has a market capitalization of $59.16 billion, a PE ratio of 13.95, a P/E/G ratio of 2.11 and a beta of 0.33.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The company had revenue of $3.03 billion for the quarter, compared to analysts' expectations of $3.40 billion. During the same period last year, the company posted $9.55 EPS. The business's revenue for the quarter was down 3.7% compared to the same quarter last year. Analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th were issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.64%. The ex-dividend date of this dividend was Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.96%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.